CpG Methylation Analysis—Current Status of Clinical Assays and Potential Applications in Molecular Diagnostics : A Report of the Association for Molecular Pathology
AUTOR(ES)
Sepulveda, Antonia R.
FONTE
American Society for Investigative Pathology
RESUMO
Methylation of CpG islands in gene promoter regions is a major molecular mechanism of gene silencing and underlies both cancer development and progression. In molecular oncology, testing for the CpG methylation of tissue DNA has emerged as a clinically useful tool for tumor detection, outcome prediction, and treatment selection, as well as for assessing the efficacy of treatment with the use of demethylating agents and monitoring for tumor recurrence. In addition, because CpG methylation occurs early in pre-neoplastic tissues, methylation tests may be useful as markers of cancer risk in patients with either infectious or inflammatory conditions. The Methylation Working Group of the Clinical Practice Committee of the Association of Molecular Pathology has reviewed the current state of clinical testing in this area. We report here our summary of both the advantages and disadvantages of various methods, as well as the needs for standardization and reporting. We then conclude by summarizing the most promising areas for future clinical testing in cancer molecular diagnostics.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2710701Documentos Relacionados
- Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands.
- A Comprehensive Analysis of Allelic Methylation Status of CpG Islands on Human Chromosome 21q
- MethySYBR, a Novel Quantitative PCR Assay for the Dual Analysis of DNA Methylation and CpG Methylation Density
- Progressive increases in the methylation status and heterochromatinization of the myoD CpG island during oncogenic transformation.
- Lsh, a modulator of CpG methylation, is crucial for normal histone methylation